Google Deepmind has introduced AlphaGenome 2, an advanced AI model designed to analyze genetic variants with single cell type precision. According to The Decoder, this new model was trained on over 107 million cell profiles, enabling it to identify nearly twice as many disease-relevant gene changes compared to its predecessor.
The Decoder also reported that AlphaGenome 2 is now accessible for noncommercial research via an API and is set to be integrated into Google's agentic platform, Antigravity. This integration aims to enhance the platform's capabilities in genetic data interpretation and biomedical applications.
For Japanese markets, where biotech innovation and AI integration are rapidly growing, AlphaGenome 2's release highlights the increasing role of AI-driven genomics in advancing personalized medicine and drug discovery within the region.